sublingual glp 1 GLP-1 for Weight Loss: or Injection sublingual semaglutide dose Weight Loss

143: 43974408 [DOI] [PubMed] [Google Scholar] 86.Wang Q, Brubaker PL

A total of 50 participants (35 patients with primary polydipsia and 15 controls) were enrolled

Food and Drug Administration (FDA) has approved Eli Lilly and Company's ZepboundTM (tirzepatide) injection, marking it as the first and only obesity treatment that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors

Other interactions: Enhanced glucose-lowering effect: alcohol, anabolic steroids, MAOIs, testosterone

Across the three treatment groups (dulaglutide 1.5 mg, dulaglutide 0.75 mg, and placebo), there were no cases of diabetic ketoacidosis or amputations, and hypotensive episodes/syncope occurred in 0%, 1% and 1%, genital infections in 0%, 0% and 1%, fractures in 1%, 1% and 1%, and gastrointestinal events in 32%, 21% and 17% of patients, respectively [31]

GLP-1 Injections are not for use in patients with Type 1 Diabetes